Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Lotem Michal

Researchers

Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, et al. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer 2021;21(1).

(2) Avner M, Orevi M, Caplan N, Popovtzer A, Lotem M, Cohen JE. COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma. Eur J Nucl Med Mol Imaging 2021;48(8):2659-2660.

(3) Hajaj E, Zisman E, Tzaban S, Merims S, Cohen J, Klein S, et al. Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T-cell effector functions. Cancer Immunol Res 2021;9(6):637-650.

(4) Ghosh S, Nataraj NB, Noronha A, Patkar S, Sekar A, Mukherjee S, et al. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Rep 2021;35(8).

(5) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22(5):655-664.

(6) Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22(5):643-654.

(7) Maddalena M, Mallel G, Nataraj NB, Shreberk-Shaked M, Hassin O, Mukherjee S, et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc Natl Acad Sci U S A 2021;118(23).

(8) Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 2021;592(7852):138-143.

(9) Long GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, et al. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. Ann Oncol 2021.

(10) Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, et al. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. J Clin Invest 2021;131(20).

(11) Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, et al. KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer 2020;8(2).

(12) Kalaora S, Lee JS, Barnea E, Levy R, Greenberg P, Alon M, et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nat Commun 2020;11(1).

(13) Kucukkaraduman B, Turk C, Fallacara AL, Isbilen M, Senses KM, Ayyildiz ZO, et al. Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells. ACS Med Chem Lett 2020;11(5):928-932.

(14) Hirshoren N, Yoeli R, Cohen JE, Weinberger JM, Kaplan N, Merims S, et al. Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. PLoS ONE 2020;15(4).

(15) Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, David IB, et al. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. eLife 2020;9.

(16) Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G, et al. Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study. Front Oncol 2020;10.

(17) Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, et al. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. J Transl Med 2019;17(1).

(18) Robert C, Ribas A, Schachter J, Arance A, Grob J-, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019;20(9):1239-1251.

(19) Pollack RM, Kagan M, Lotem M, Dresner-Pollak R. Baseline TSH level is associated with risk of anti–PD-1–induced thyroid dysfunction. Endocr Pract 2019;25(8):824-829.

(20) Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 2019;25(6):941-946.

(21) Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, et al. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. J Am Acad Dermatol 2019;80(6):1780-1782.

(22) Weinstein-Marom H, Levin N, Pato A, Shmuel N, Sharabi-Nov A, Peretz T, et al. Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells. J Immunother 2019;42(2):43-50.

(23) Levin N, Weinstein-Marom H, Pato A, Itzhaki O, Besser MJ, Eisenberg G, et al. Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40. J Immunol 2018;201(10):2959-2968.

(24) Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov 2018;8(11):1366-1375.

(25) Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, et al. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clin Chem Lab Med 2018;56(11):1945-1953.

(26) Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, et al. Neurologic complications of immune checkpoint inhibitors. J Neuro-Oncol 2018;137(3):601-609.

(27) Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, et al. Soluble SLAMF6 receptor induces strong CD8\+ T-cell effector function and improves anti-melanoma activity in vivo. Cancer Immunol Res 2018;6(2):127-138.

(28) Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 2017;8(1).

(29) Schachter J, Ribas A, Long GV, Arance A, Grob J-, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390(10105):1853-1862.

(30) Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, et al. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine 2017;96(20).

(31) Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Adoptive cell therapy: Past, present and future. Immunother 2017;9(2):183-196.

(32) Senses KM, Ghasemi M, Akbar MW, Isbilen M, Fallacara AL, Frankenburg S, et al. Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma. MedChemComm 2017;8(1):88-95.

(33) Kuint R, Lotem M, Neuman T, Bekker-Milovanov E, Abutbul A, Laxer U, et al. Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report. Respir Med Case Rep 2017;20:95-97.

(34) Levin N, Pato A, Cafri G, Eisenberg G, Peretz T, Margalit A, et al. Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40. J Immunother 2017;40(2):39-50.

(35) Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical significance of circulating CD33+ CD11bHLA-DR myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin Cancer Res 2016;22(23):5661-5672.

(36) Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, et al. Immune monitoring of patients treated with a whole-cell melanoma vaccine engineered to express 4-1BBL. J Immunother 2016;39(8):321-328.

(37) Ollech A, Stemmer SM, Merims S, Lotem M, Popovtzer A, Hendler D, et al. Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. Int J Dermatol 2016;55(4):473-478.

(38) Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, et al. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. J Immunol Res 2016;2016.

(39) Weinstein-Marom H, Pato A, Levin N, Susid K, Itzhaki O, Besser MJ, et al. Membrane-attached cytokines expressed by mRNA electroporation act as potent T-cell adjuvants. J Immunother 2016;39(2):60-70.

(40) Barak V, Leibovici V, Peretz T, Kalichman I, Lotem M, Merims S. Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. Anticancer Res 2015;35(12):6755-6760.

(41) Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, et al. Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. Clin Exp Immunol 2015;182(2):220-229.

(42) Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med 2015;372(26):2521-2532.

(43) Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, et al. Human T cell crosstalk is induced by tumor membrane transfer. PLoS ONE 2015;10(2).

(44) Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget 2014;5(7):1701-1752.

(45) Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, et al. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J Immunol 2013;190(11):5856-5865.

(46) Yaacov B, Lazar I, Tayeb S, Frank S, Izhar U, Lotem M, et al. Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. J Gen Virol 2012;93(8):1664-1672.

(47) Lazar I, Perlman R, Lotem M, Peretz T, Ben-Yehuda D, Kadouri L. The clinical effect of the inhibitor of apopotosis protein livin in melanoma. Oncology (Switzerland) 2012;82(4):197-204.

(48) Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, et al. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8 + T cell clones. J Immunol 2012;188(2):632-640.

(49) Lotem M, Merims S, Frank S, Ospovat I, Peretz T. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma]. Harefuah 2012;151(10):585-588, 604.

(50) Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, et al. HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine. Tissue Antigens 2011;78(3):203-207.

(51) Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011;364(26):2517-2526.

(52) Eisenberg G, Machlenkin A, Frankenburg S, Mansura A, Pitcovski J, Yefenof E, et al. Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response. Cell Immunol 2010;266(1):98-103.

(53) Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein livin. J Virol 2010;84(1):639-646.

(54) Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, et al. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol Immunother 2010;59(1):103-112.

(55) Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, et al. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clin Cancer Res 2009;15(15):4968-4977.

(56) Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009;93(8):1042-1046.

(57) Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, et al. Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 2009;8(1):29-32.

(58) Gross M, Maly B, Maly A, Lotem M, Eliashar R. Metastatic Malignant Melanoma Involving the Parotid Lymph Node Region: A Clinicopathologic Report of 5 Cases. J Oral Maxillofac Surg 2008;66(4):809-813.

(59) Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, et al. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Res 2008;68(6):2006-2013.

(60) Levy A, Pitcovski J, Frankenburg S, Elias O, Altuvia Y, Margalit H, et al. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response. Cell Immunol 2007;250(1-2):24-30.

(61) Molho-Pessach V, Lotem M. Ultraviolet radiation and cutaneous carcinogenesis. Curr Probl Dermatol 2007;35:14-27.

(62) Molho-Pessach V, Lotem M. Viral carcinogenesis in skin cancer. Curr Probl Dermatol 2007;35:39-51.

(63) Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4+ T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 2007;67(9):4499-4506.

(64) Salah Z, Maoz M, Pokroy E, Lotem M, Bar-Shavit R, Uziely B. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol Cancer Res 2007;5(3):229-240.

(65) Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J Immunother 2006;29(6):616-627.

(66) Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients. Ann Oncol 2006;17(4):578-583.

(67) Enk CD, Lotem M, Gimon Z, Hochberg M. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Res 2004;14(5):361-365.

(68) Frankenburg S, Elias O, Gelbart Y, Drize O, Lotem M, Ingber A, et al. Recombinant hydrophilic human gp100: Uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients. Immunol Lett 2004;94(3):253-259.

(69) Hodak E, Gottlieb AB, Segal T, Maron L, Lotem M, Feinmesser M, et al. An open trial of climatotherapy at the dead sea for patch-stage mycosis fungoides. J Am Acad Dermatol 2004;51(1):33-38.

(70) Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 2004;90(4):773-780.

(71) Lieberman S, Goldin E, Lotem M, Bloom AI. Irrigation of the bile ducts with chilled saline during percutaneous radiofrequency ablation of a hepatic ocular melanoma metastasis. Am J Roentgenol 2004;183(3):596-598.

(72) Gelbart Y, Frankenburg S, Pinchasov Y, Krispel S, Eliahu D, Drize O, et al. Production and purification of melanoma gp100 antigen and polyclonal antibodies. Protein Expr Purif 2004;34(2):183-189.

(73) Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al. Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res 2003;63(19):6340-6349.

(74) Lotem M, Yehuda-Gafni O, Butnaryu E, Drize O, Peretz T, Abeliovich D. Cytogenetic analysis of melanoma cell lines: Subclone selection in long-term melanoma cell cultures. Cancer Genet Cytogenet 2003;142(2):87-91.

(75) Lotem M, Anteby S, Peretz T, Ingber A, Avinoach I, Prus D. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol 2003;88(1):45-50.

(76) Lotem M, Peretz T, Drize O, David IB, Hamburger T, Gimmon Z. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). Br J Cancer 2002;86(10):1534-1539.

(77) Hochberg M, Lotem M, Gimon Z, Shiloni E, Enk CD. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. Br J Dermatol 2002;146(2):244-249.

(78) Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, et al. CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002;168(6):2803-2810.

(79) Lotem M, Peretz T, Drize O, David IB, Hamburger T, Gimmon Z. Special section on nonparametric approach to time series analysis. Annal Inst Stat Math 2002;54(1):169.

(80) Lotem M, Raben M, Zeltser R, Landau M, Sela M, Wygoda M, et al. Kindler syndrome complicated by squamous cell carcinoma of the hard palate: Successful treatment with high-dose radiation therapy and granulocyte-macrophage colony-stimulating factor [18]. Br J Dermatol 2001;144(6):1284-1286.

(81) Pappo I, Lotem M, Klein M, Orda R. Bolus high dose interleukin-2 for the treatment of malignant melanoma. Isr Med Assoc J 2001;3(3):169-173.

(82) Hazzan D, Reissmann P, Halak M, Resnick MB, Lotem M, Shiloni E. Primary rectal malignant melanoma: Report of two cases. Tech Coloproctol 2001;5(1):51-54.

(83) Yakobson E, Shemesh P, Azizi E, Winkler E, Lassam N, Hogg D, et al. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 2000;8(8):590-596.

(84) Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer 2000;89(5):1037-1047.

(85) Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000;136(12):1475-1480.

(86) Klein M, Freedman N, Lotem M, Marciano R, Moshe S, Gimon Z, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: A pilot study. Nuklearmedizin 2000;39(3):56-61.

(87) Hirshberg B, Kramer MR, Lotem M, Barak V, Shustin L, Amir G, et al. Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma. Am J Hematol 1999;60(2):143-147.

(88) Lotem M, Shiloni E, Ingber A, Peretz T. Active specific immunotherapy of malignant melanoma. Harefuah 1997;133(3-4):122-126.

(89) Tsur A, Sazbon L, Lotem M. Relationship between muscular tone, movement and periarticular new bone formation in postcoma-unaware (PC-U) patients. Brain Inj 1996;10(4):259-262.

(90) Lotem M, Tamir G, Loven D, David M, Hauben D. Multiple basal cell carcinomas of the leg after recurrent erysipelas and chronic lymphedema. J Am Acad Dermatol 1994;31(5):812-813.

(91) Lotem M, Trattner A, Ingber A. Paraneoplastic Pemphigus: Reevaluation of a Case From the Past. Arch Dermatol 1994;130(11):1454.

(92) Tsur A, Sazbon L, Lotem M. Influence of muscle tone and force on ossification in postcomatose patients. Harefuah 1992;123(3-4):86-89, 156-157.

(93) LOTEM M, TRATTNER A, KAHANOVICH S, ROTEM A, SANDBANK M. MULTIPLE DERMAL CYLINDROMA UNDERGOING A MALIGNANT TRANSFORMATION. Int J Dermatol 1992;31(9):642-644.

(94) Lotem M, Birch JG, Herring JA, Roach JW, Johnston II CE, Viere RG. Letter to the editor [3]. J BONE JT SURG SER A 1991;73(3):472.

(95) Lotem M, Ingber A, Segal R, Sandbank M. Generalized pustular drug rash induced by hydroxychloroquine. ACTA DERM -VENEREOL 1990;70(3):250-251.

(96) Katzenelson V, Lotem M, Sandbank M. Familial lichen planus. Dermatologica 1990;180(3):166-168.

(97) Halevy S, Arie R, Ingber A, Lotem M, Sandbank M. Analysis of lithogenous factors in lichen planus. ACTA DERM -VENEREOL 1990;70(5):441-442.

(98) Lotem M, Ingber A, Sandbank M, Hazaz B. Lichen Planus Pemphigoides With Features of Lichen Planus and Pemphigus Vulgaris. Arch Dermatol 1989;125(5):707-708.

(99) Lotem M, Katzenelson V, Sandbank M, Hod M, Sandbank M. Impetigo herpetiformis: A variant of pustular psoriasis or a separate entity? J Am Acad Dermatol 1989;20(2):338-341.

(100) Lotem M, Ingber A, Filhaber A, Sandbank M. Skin infection provoked by coagulase-negative Staphylococcus resembling gram-negative folliculitis. Cutis 1988;42(5):443-444.

(101) Davidovitch E, Lotem M, Hallel T. Malignant fibrous histiocytoma. Harefuah 1988;115(1-2):13-15.

(102) Sagiv P, Lotem M, Solan H, Hallel T. Metatarsus adductus--incidence and treatment. Harefuah 1986;110(8):394-397.

(103) Houpt JB, Alpert B, Lotem M, Greyson ND, Pritzker KP, Langer F, et al. Spontaneous osteonecrosis of the medial tibial plateau. J Rheumatol 1982;9(1):81-90.

(104) Groswasser Z, Lotem M, Mendelson L. Treatment of femoral fractures in patients with craniocerebral injury. Int Surg 1982;67(4 Suppl.):556-558.

(105) Greyson ND, Lotem MM, Gross AE, Houpt JB. Radionuclide evaluation of spontaneous femoral osteonecrosis. Radiology 1982;142(3):729-735.

(106) Lotem M, Davidovitz E. Malignant fibrous histiocytoma. Harefuah 1980;98(5):216-218+239.

(107) Conforty B, Lotem M. Ossicles in human menisci: report of two cases. Clin Orthop 1979(144):272-275.

(108) Lotem M, Bernheim J, Conforty B. Spontaneous rupture of tendons. A complication of hemodialyzed patients treated for renal failure. Nephron 1978;21(4):201-208.

(109) Lotem M. Medical aspects and prevention of road accidents and the treatment of the injured. FAM PHYS 1976;5(3):36.

(110) Lotem M, Conforty B. High pressure injection injuries of the hand (Hebrew). Harefuah 1975;89(5):213-215+239.

(111) Lotem M, Wolloch J. Postoperative peripheral nerve injury. Harefuah 1975;88(8):379-380.

(112) Lotem M, Selenfreund M. Hemangiomatosis of the tibia (Hebrew). Harefuah 1975;88(10):464-465+495.

(113) Lotem M, Solzi P. The carpal tunnel syndrome (Hebrew). FAM PHYS 1975;5(1):61-63+12.

(114) Lotem M, Robson MD, Rosenfeld JB. Spontaneous rupture of the quadriceps tendon in patients on chronic haemodialysis. Ann Rheum Dis 1974;33(5):428-429.

(115) Lotem M, Maor P, Levi M. Rupture of the extensor tendons of the hand in lupus erythematosus disseminatus. Ann Rheum Dis 1973;32(5):457-459.

(116) Levy M, Pauker M, Lotem M, Seelenfreund M, Fried A. High tibial osteotomy: a follow up study and description of a modified technic. Clin Orthop 1973;93:274-277.

(117) Pauker M, Lotem M, Levy M, Luria M. BCG arthritis and osteomyelitis. Harefuah 1972;83(10):429-432.

(118) Lotem M, Fried A, Solzi P, Natanson T. Saturday night palsy. Harefuah 1972;83(8):328.

(119) Maor P, Levy M, Lotem M, Fried A. Iatrogenic Volkmann's ischemia--a result of pressure-transfusion. Int Surg 1972;57(5):415-416.

(120) Fried A, Lotem M. Local infiltration anesthesia for meniscectomy. Clin Orthop Relat Res 1972;87:204-205.

(121) Lotem M, Maor P, Fried A. Posterior interosseous nerve palsy. Harefuah 1971;81(8):377-379.

(122) Lotem M, Fried A. Operative treatment of degenerative tears of the semilunar cartilage. A follow-up study. Isr J Med Sci 1971;7(6):733-737.

(123) Lotem M, Maor P, Haimoff H, Woloch Y. Lumbar hernia at an iliac bone graft donor site. A case report. Clin Orthop Relat Res 1971;80:130-132.

(124) Lotem M, Fried A, Levy M, Solzi P, Najenson T, Nathan H. Radial palsy following muscular effort. A nerve compression syndrome possibly related to a fibrous arch of the lateral head of the triceps. J Bone Joint Surg Br 1971;53(3):500-506.

(125) Lotem M, Solsi P. Transient radial palsy following muscular effort. Harefuah 1970;78(10):490-491.

(126) Levy M, Lotem M, Fried A. The Laurence-Moon-Biedl-Bardet syndrome. Report of three cases in a Jewish Yemenite family. J Bone Joint Surg Br 1970;52(2):318-324.